SRC
AKBA icon

Shufro Rose & Co’s Akebia Therapeutics AKBA Stock Holding History

Shufro Rose & Co’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-27,969
Closed -$110K – 316
2019
Q3 		$110K Sell
27,969
-1,122
-4% -$4.81K 0.01% 296
2019
Q2 		$141K Buy
29,091
+664
+2% +$3.78K 0.01% 277
2019
Q1 		$233K Sell
28,427
-561
-2% -$3.85K 0.02% 248
2018
Q4 		$160K Buy
+28,988
New +$227K 0.02% 257

Other funds holding AKBA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Shufro Rose & Co's AKBA Position: Q4 2019 in Review

Shufro Rose & Co sold out of Akebia Therapeutics (AKBA) in Q4 2019, closing a stake of 27,969 shares — an estimated $110K sold.

Shufro Rose & Co first reported a position in AKBA in Q4 2018 and held it in 4 quarters. The position peaked at $233K in Q1 2019. 153 funds tracked by Wall St. Rank hold AKBA as of Q4 2019.

  • Shufro Rose & Co reported no remaining Akebia Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Shufro Rose & Co sold 27,969 Akebia Therapeutics shares in Q4 2019, an estimated $110K.
  • Shufro Rose & Co first reported a position in Akebia Therapeutics in Q4 2018 and held it in 4 quarters.
  • Shufro Rose & Co's Akebia Therapeutics position peaked at $233K in Q1 2019.
  • 153 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2019.

Based on Shufro Rose & Co's 13F filing for Q4 2019, filed 28 Jan 2020.